Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
arexvy + abrysvo
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Arexvy + Abrysvo is a combination of two recombinant subunit vaccines used for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV). Both vaccines target the RSV F protein in its prefusion conformation to stimulate an immune response and generate protective antibodies. Arexvy contains a recombinant RSVPreF3 antigen adjuvanted with AS01E (containing MPL and QS-21), while Abrysvo is a bivalent, unadjuvanted vaccine containing stabilized prefusion F proteins from both RSV A and B subtypes. Both are approved for use in adults aged 60 years and older; Abrysvo is also approved for pregnant individuals to protect infants up to six months old. The mechanism of action involves induction of immunity against the prefusion F protein, preventing viral attachment and infection[1][2][4][6].
- Other names
- RSV vaccine pref3, recombinant + bivalent RSVpreF vaccine
02
Targets
RSV-A PreF (Respiratory syncytial virus subtype A prefusion fusion glycoprotein)RSV preF (Respiratory syncytial virus prefusion F glycoprotein)
Beyond the preview
Go deeper on arexvy + abrysvo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on arexvy + abrysvo.